(19)
(11) EP 2 971 102 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
15.08.2018 Bulletin 2018/33

(45) Mention of the grant of the patent:
20.06.2018 Bulletin 2018/25

(21) Application number: 14721636.0

(22) Date of filing: 14.03.2014
(51) International Patent Classification (IPC): 
C12Q 1/68(2018.01)
 C12N 15/113(2010.01)
(86) International application number:
PCT/US2014/027587
(87) International publication number:
WO 2014/152659 (25.09.2014 Gazette 2014/39)

(54)

QUANTITATIVE ASSESSMENT FOR CAP EFFICIENCY OF MESSENGER RNA

QUANTITATIVE BESTIMMUNG DER CAPPING EFFIZIENZ VON MRNA

ÉVALUATION QUANTITATIVE POUR L'EFFICACITÉ DE COIFFAGE DE L'ARN MESSAGER

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA ME

(30) Priority: 14.03.2013 US 201361784337 P

(43) Date of publication of application:
20.01.2016 Bulletin 2016/03

(73) Proprietor: Translate Bio, Inc.
Lexington, MA 02421 (US)

(72) Inventors:
  • HEARTLEIN, Michael
    Lexington, Massachusetts 02421 (US)
  • DEROSA, Frank
    Lexington, Massachusetts 02421 (US)
  • DIAS, Anusha
    Lexington, Massachusetts 02421 (US)

(74) Representative: Carpmaels & Ransford LLP 
One Southampton Row
London WC1B 5HA
London WC1B 5HA (GB)


(56) References cited: : 
US-A1- 2012 251 618
   
  • TCHEREPANOVA IRINA Y ET AL: "Ectopic expression of a truncated CD40L protein from synthetic post-transcriptionally capped RNA in dendritic cells induces high levels of IL-12 secretion", BMC MOLECULAR BIOLOGY, BIOMED CENTRAL LTD, GB, vol. 9, no. 1, 17 October 2008 (2008-10-17), page 90, XP021042442, ISSN: 1471-2199, DOI: 10.1186/1471-2199-9-90
  • THEUS S A ET AL: "A simple assay for determining the capping efficiencies of RNA polymerases used for in vitro transcription", BIOTECHNIQUES, INFORMA HEALTHCARE, US, vol. 9, no. 5, 1 November 1990 (1990-11-01), pages 610-612,614, XP009179072, ISSN: 0736-6205
  • KORE A R ET AL: "Synthesis and evaluation of 2'-O-allyl substituted dinucleotide cap analog for mRNA translation", BIOORGANIC & MEDICINAL CHEMISTRY, PERGAMON, GB, vol. 18, no. 22, 15 November 2010 (2010-11-15), pages 8061-8065, XP027452470, ISSN: 0968-0896, DOI: 10.1016/J.BMC.2010.09.013 [retrieved on 2010-09-19]
  • KORE ET AL: "Synthesis and biological evaluation of trimethyl-substituted cap analogs", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, AMSTERDAM, NL, vol. 18, no. 3, 4 January 2008 (2008-01-04), pages 880-884, XP022475650, ISSN: 0960-894X, DOI: 10.1016/J.BMCL.2007.12.049
  • GRUDZIEN EWA ET AL: "Novel cap analogs for in vitro synthesis of mRNAs with high translational efficiency", RNA, COLD SPRING HARBOR LABORATORY PRESS, US, vol. 10, no. 9, 1 September 2004 (2004-09-01), pages 1479-1487, XP002452227, ISSN: 1355-8382, DOI: 10.1261/RNA.7380904
  • JEMIELITY J ET AL: "Novel anti-reverse cap analogs with superior translational properties", RNA, COLD SPRING HARBOR LABORATORY PRESS, US, vol. 9, no. 9, 1 September 2003 (2003-09-01), pages 1108-1122, XP002378472, ISSN: 1355-8382, DOI: 10.1261/RNA.5430403
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).